Renaissance Technologies LLC Buys 365,441 Shares of Entera Bio Ltd. $ENTX

Key Points

• Renaissance Technologies increased its Entera Bio stake by 338.4%, buying 365,441 additional shares to own 473,442 shares, or about 0.96% of the company. Institutional investors and hedge funds collectively own 14.11% of ENTX.
• Analyst sentiment is mixed, with one Buy and one Sell rating; MarketBeat reports an average rating of Hold and a $9.00 price target.
• Entera Bio reported a quarterly loss of $0.14 per share, missing the $0.08 consensus loss estimate. ENTX opened at $2.90, compared with a 12-month range of $0.91 to $4.20.

Renaissance Technologies LLC raised its stake in Entera Bio Ltd. (NASDAQ:ENTX - Free Report) by 338.4% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 473,442 shares of the company's stock after acquiring an additional 365,441 shares during the period. Renaissance Technologies LLC owned approximately 0.96% of Entera Bio worth $526,000 at the end of the most recent quarter.

Several other large investors also recently modified their holdings of ENTX. Superstring Capital Management LP acquired a new position in Entera Bio in the fourth quarter valued at about $33,000. HighTower Advisors LLC increased its holdings in Entera Bio by 137.8% in the 4th quarter. HighTower Advisors LLC now owns 43,140 shares of the company's stock valued at $84,000 after buying an additional 25,000 shares during the period. Citadel Advisors LLC increased its holdings in Entera Bio by 243.0% in the 3rd quarter. Citadel Advisors LLC now owns 39,978 shares of the company's stock valued at $77,000 after buying an additional 28,322 shares during the period. Schonfeld Strategic Advisors LLC raised its position in shares of Entera Bio by 5.2% in the 4th quarter. Schonfeld Strategic Advisors LLC now owns 596,585 shares of the company's stock valued at $1,157,000 after buying an additional 29,629 shares in the last quarter. Finally, Jane Street Group LLC raised its position in shares of Entera Bio by 142.6% in the 4th quarter. Jane Street Group LLC now owns 74,064 shares of the company's stock valued at $144,000 after buying an additional 43,536 shares in the last quarter. 14.11% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several research firms recently issued reports on ENTX. Weiss Ratings reiterated a "sell (d-)" rating on shares of Entera Bio in a research report on Friday, July 17th. HC Wainwright restated a "buy" rating on shares of Entera Bio in a research report on Wednesday, June 24th. Finally, Wall Street Zen raised Entera Bio to a "sell" rating in a report on Saturday, August 8th. One analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock has an average rating of "Hold" and an average price target of $9.00.

Entera Bio Trading Up 0.3%

Shares of NASDAQ ENTX opened at $2.90 on Tuesday. The company has a market cap of $502.11 million, a price-to-earnings ratio of -8.29 and a beta of 1.38. Entera Bio Ltd. has a 12 month low of $0.91 and a 12 month high of $4.20. The stock has a 50-day moving average price of $2.05 and a two-hundred day moving average price of $1.55.

Entera Bio (NASDAQ:ENTX - Get Free Report) last posted its quarterly earnings results on Friday, August 7th. The company reported ($0.14) earnings per share for the quarter, missing analysts' consensus estimates of ($0.08) by ($0.06). On average, sell-side analysts predict that Entera Bio Ltd. will post -0.34 earnings per share for the current year.

Entera Bio Company Profile

Entera Bio, Inc is a clinical‐stage biopharmaceutical company pioneering the development of orally delivered peptide therapeutics. Utilizing its proprietary oral delivery platform, Entera Bio seeks to overcome the challenges of gastrointestinal absorption for large peptide molecules. The technology is designed to facilitate transit across the intestinal epithelium while preserving peptide structure and bioactivity, offering the potential for daily oral dosing in lieu of injectable formulations.

The company's lead candidate, EB613, is an oral parathyroid hormone (PTH) analog under investigation for the treatment of osteoporosis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source